Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) has announced the granting of 73,500 restricted stock units (RSUs) to 12 new employees under its 2017 Inducement Equity Incentive Plan. The RSUs will vest 25% after one year, with the remaining 75% vesting in twelve equal quarterly installments thereafter, contingent on continued employment.
Esperion is a commercial-stage biopharmaceutical company developing FDA-approved oral, non-statin medicines for cardiovascular disease patients with elevated LDL-C. The company is also advancing its next-generation ATP citrate lyase inhibitor (ACLYi) program, leveraging new insights for developing highly potent and specific inhibitors.
Esperion (NASDAQ: ESPR) ha annunciato la concessione di 73.500 unit脿 azionarie vincolate (RSU) a 12 nuovi dipendenti nell'ambito del suo Piano di Incentivi Azionari del 2017. Le RSU matureranno per il 25% dopo un anno, mentre il restante 75% maturer脿 in dodici rate trimestrali uguali, subordinatamente alla permanenza in azienda.
Esperion 猫 un'azienda biofarmaceutica in fase commerciale che sviluppa farmaci orali approvati dalla FDA, non a base di statine, per pazienti con malattie cardiovascolari e livelli elevati di LDL-C. L'azienda sta inoltre portando avanti il suo programma di inibitori di nuova generazione della ATP citrato liasi (ACLYi), sfruttando nuove conoscenze per sviluppare inibitori altamente potenti e specifici.
Esperion (NASDAQ: ESPR) ha anunciado la concesi贸n de 73,500 unidades de acciones restringidas (RSU) a 12 nuevos empleados bajo su Plan de Incentivos de Acciones por Inducci贸n de 2017. Las RSU se consolidar谩n en un 25% despu茅s de un a帽o, y el 75% restante se consolidar谩 en doce cuotas trimestrales iguales, condicionado a la continuidad laboral.
Esperion es una empresa biofarmac茅utica en etapa comercial que desarrolla medicamentos orales aprobados por la FDA, no basados en estatinas, para pacientes con enfermedades cardiovasculares y niveles elevados de LDL-C. La compa帽铆a tambi茅n est谩 avanzando en su programa de inhibidores de ATP citrato liasa (ACLYi) de pr贸xima generaci贸n, aprovechando nuevos conocimientos para desarrollar inhibidores altamente potentes y espec铆ficos.
鞐愳姢韼橂Μ鞓� (NASDAQ: ESPR)鞚� 2017雲� 鞙犾澑順� 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 12氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 73,500臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 攵�鞐枅雼り碃 氚滍憸頄堨姷雼堧嫟. RSU電� 1雲� 頉� 25%臧� 氩犾姢韺呺悩氅�, 雮橂ǜ歆� 75%電� 瓿勳啀 攴茧 臁瓣贝 頃橃棎 12臧滌潣 霃欖澕頃� 攵勱赴氤� 頃犽秬搿� 氩犾姢韺呺惄雼堧嫟.
鞐愳姢韼橂Μ鞓潃 FDA 鞀轨澑霅� 瓴疥惮鞖� 牍勳姢韮�韹搓硠 鞎诫鞚� 臧滊皽頃橂姅 靸侅梾 雼硠鞚� 靸濍獏瓿淀暀 鞝滌暯 須岇偓搿�, LDL-C 靾橃箻臧� 雴掛潃 鞁槇甏� 歆堩櫂 頇橃瀽毳� 雽�靸侅溂搿� 頃╇媹雼�. 霕愴暅, 彀劯雽� ATP 鞁滍姼毳挫偘 攵勴暣須唽(ACLYi) 鞏奠牅鞝� 頂勲攴鸽灗鞚� 歆勴枆頃橂┌, 雴掛潃 須姤瓿� 韸轨澊靹膘潉 臧�歆� 鞏奠牅鞝� 臧滊皽鞚� 鞙勴暅 靸堧鞖� 韱奠鞍鞚� 頇滌毄頃橁碃 鞛堨姷雼堧嫟.
Esperion (NASDAQ : ESPR) a annonc茅 l'attribution de 73 500 unit茅s d'actions restreintes (RSU) 脿 12 nouveaux employ茅s dans le cadre de son Plan d'Incitation en Actions de 2017. Les RSU seront acquises 脿 hauteur de 25 % apr猫s un an, le reste (75 %) 茅tant acquis en douze versements trimestriels 茅gaux, sous r茅serve de la poursuite de l'emploi.
Esperion est une soci茅t茅 biopharmaceutique en phase commerciale d茅veloppant des m茅dicaments oraux non-statines approuv茅s par la FDA pour les patients atteints de maladies cardiovasculaires avec un taux 茅lev茅 de LDL-C. La soci茅t茅 fait 茅galement progresser son programme d'inhibiteurs de l'ATP citrate lyase (ACLYi) de nouvelle g茅n茅ration, en s'appuyant sur de nouvelles connaissances pour d茅velopper des inhibiteurs tr猫s puissants et sp茅cifiques.
Esperion (NASDAQ: ESPR) hat die Gew盲hrung von 73.500 Restricted Stock Units (RSUs) an 12 neue Mitarbeiter im Rahmen seines Inducement Equity Incentive Plans von 2017 bekannt gegeben. Die RSUs werden zu 25 % nach einem Jahr f盲llig, die restlichen 75 % werden danach in zw枚lf gleichen viertelj盲hrlichen Raten freigegeben, vorbehaltlich einer fortgesetzten Besch盲ftigung.
Esperion ist ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das von der FDA zugelassene orale, nicht-statinbasierte Medikamente f眉r Patienten mit Herz-Kreislauf-Erkrankungen und erh枚htem LDL-C entwickelt. Das Unternehmen treibt au脽erdem sein Programm der n盲chsten Generation von ATP-Citrat-Lyase-Inhibitoren (ACLYi) voran und nutzt neue Erkenntnisse zur Entwicklung hochwirksamer und spezifischer Inhibitoren.
- None.
- Equity grants may lead to future dilution for existing shareholders
ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion鈥檚 2017 Inducement Equity Incentive Plan.
The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Each RSU will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient鈥檚 vesting commencement date and will vest and become exercisable as to the remaining 75 percent of the shares in twelve equal quarterly installments at the end of each quarter following such anniversary, in each case, subject to each such employee's continued employment with Esperion on such vesting dates. The RSUs are subject to the terms and conditions of Esperion鈥檚 2017 Inducement Equity Incentive Plan, and the terms and conditions of the RSU agreement covering the grant.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit and follow Esperion on and .
Esperion Contact Information:听
Investors:听听
Alina Venezia听
(734) 887-3903听
Media:听听
Tiffany Aldrich听听
(616) 443-8438听
FAQ
What type of equity grants did Esperion (ESPR) announce in August 2025?
How will the RSUs vest for new Esperion employees?
What is Esperion's main product focus?
What new research area is Esperion developing?
How many patients were involved in Esperion's CLEAR Cardiovascular Outcomes Trial?
